Featured 13F manager
DAFNA Capital Management LLC Nathan Fischel
Los Angeles, CA 20 processed 13Fs on this site · 2021 Q3–2026 Q2
- $524M
- 88 Positions
- 2026 Q2
- +19.1% QoQ
- Top 5 40.2%
Nathan Fischel files DAFNA Capital Management LLC as a Form 13F. The latest book is 2026 Q2 at $524M, up 19.1% QoQ, led by Revolution Medicines, Spdr S&P Biotech ETF, and Compass Pathways.
Portfolio
top 5 40.2% · top 10 56.2%
- RVMD - Revolution Medicines 20.1%
- XBI - Spdr S&P Biotech ETF 5.9%
- CMPS - Compass Pathways 5.4%
- STXS - Stereotaxis 4.5%
- NKTR - Nektar Therapeutics 4.3%
- DNLI - Denali Therapeutics 3.6%
- IDYA - Ideaya Biosciences 3.5%
- ATRC - Atricure 3.2%
- XENE - Xenon Pharmaceuticals 2.9%
- CYTK - Cytokinetics 2.8%
- RCUS - Arcus Biosciences 2.6%
- ASND - Ascendis Pharma A/S 2.5%
- Other 38.7%
AUM over time
Book
| RVMD - Revolution Medicines | 12.85% | Reduce −3.9% | 580,678 | $97.25 | $56M | −23,836 | +$8M |
| XBI - Spdr S&P Biotech ETF | 9.25% | Reduce −5.3% | 318,505 | $127.73 | $41M | −18,000 | −$347K |
| STXS - Stereotaxis | 5.73% | Hold | 13,680,554 | $1.84 | $25M | — | — |
| DAWNGBX — | 4.77% | Reduce −2.1% | 978,463 | $21.44 | $21M | −20,700 | +$12M |
| ATRC - Atricure | 3.88% | Hold | 597,431 | $28.53 | $17M | — | — |
| IDYA - Ideaya Biosciences | 3.61% | Reduce −5.9% | 476,740 | $33.32 | $16M | −30,000 | −$2M |
| XENE - Xenon Pharmaceuticals | 3.32% | Reduce −12.9% | 250,772 | $58.15 | $15M | −37,167 | +$2M |
| CYTK - Cytokinetics | 3.26% | Reduce −41.4% | 217,497 | $65.91 | $14M | −153,500 | −$9M |
| CMPS - Compass Pathways | 3.04% | Add +198.2% | 2,418,882 | $5.53 | $13M | +1,607,836 | +$8M |
| NKTR - Nektar Therapeutics | 2.70% | Add +120.2% | 165,178 | $71.95 | $12M | +90,180 | +$9M |
| NDAQ - Ishares Nasdaq Biotech Indx | 2.39% | Reduce −8.8% | 62,095 | $168.85 | $10M | −6,000 | −$1M |
| RCUS - Arcus Biosciences | 2.18% | Add +2.9% | 443,829 | $21.60 | $10M | +12,500 | −$692K |
| NBIX - Neurocrine Biosciences | 2.12% | Hold | 70,615 | $131.74 | $9M | — | — |
| LRMR - Larimar Therapeutics | 2.08% | Add +116.1% | 2,029,164 | $4.50 | $9M | +1,090,000 | +$6M |
| BCAX - Bicara Therapeutics | 1.91% | Add +61.2% | 421,733 | $19.89 | $8M | +160,150 | +$4M |
| AXGN - Axogen | 1.88% | Reduce −47.6% | 249,960 | $33.13 | $8M | −226,866 | −$7M |
| BHVN - Biohaven | 1.63% | Reduce −11.5% | 845,735 | $8.46 | $7M | −109,500 | −$4M |
| TNDM - Tandem Diabetes Care | 1.55% | Hold | 355,208 | $19.17 | $7M | — | — |
| DNLI - Denali Therapeutics | 1.39% | Hold | 318,500 | $19.20 | $6M | — | — |
| IPSC - Century Therapeutics | 1.25% | Reduce −12.9% | 2,434,353 | $2.26 | $6M | −359,233 | +$3M |
| DXCM - Dexcom | 1.23% | Reduce −2.3% | 86,279 | $62.80 | $5M | −2,000 | −$441K |
| Kalvista Pharmaceuticals | 1.22% | Reduce −25.1% | 267,402 | $20.13 | $5M | −89,400 | −$380K |
| ASND - Ascendis Pharma A/S | 1.21% | Reduce −17.7% | 23,177 | $228.73 | $5M | −5,000 | −$707K |
| MBX - Mbx Biosciences | 1.19% | Add +6.2% | 175,465 | $29.85 | $5M | +10,200 | +$25K |
| INGN - Inogen | 1.19% | Add +2.2% | 845,179 | $6.18 | $5M | +18,108 | −$335K |
| SNDX - Syndax Pharmaceuticals | 1.16% | Reduce −21.8% | 217,355 | $23.36 | $5M | −60,500 | −$760K |
| ALKS - Alkermes | 1.12% | Add +7.1% | 139,482 | $35.36 | $5M | +9,234 | +$1M |
| STOK - Stoke Therapeutics | 0.97% | Add +20.2% | 130,875 | $32.56 | $4M | +22,000 | +$806K |
| BCRX - Biocryst Pharmaceuticals | 0.93% | Add +2.9% | 430,248 | $9.52 | $4M | +11,993 | +$834K |
| LKFT - Galapagos | 0.89% | Hold | 130,175 | $30.00 | $4M | — | — |
| IMVT - Immunovant | 0.85% | Hold | 150,524 | $24.84 | $4M | — | — |
| EWTX - Edgewise Therapeutics | 0.80% | Reduce −29.7% | 112,236 | $31.50 | $4M | −47,500 | −$428K |
| MPLT - Maplight Therapeutics | 0.79% | Add +18.9% | 171,006 | $20.33 | $3M | +27,242 | +$951K |
| ALLO - Allogene Therapeutics | 0.76% | Reduce −0.7% | 1,370,118 | $2.44 | $3M | −10,000 | +$1M |
| PRCT - Procept Biorobotics | 0.68% | Hold | 120,000 | $25.01 | $3M | — | — |
| ALGN - Align Technology | 0.58% | Reduce −6.3% | 15,000 | $171.43 | $3M | −1,000 | +$73K |
| PRQR - Proqr Therapeutics | 0.58% | Hold | 1,567,561 | $1.62 | $3M | — | — |
| CYBN - Cybin | 0.54% | Add +9.5% | 498,361 | $4.80 | $2M | +43,343 | −$1M |
| RAPP - Rapport Therapeutics | 0.53% | Hold | 75,000 | $31.29 | $2M | — | — |
| PODD - Insulet | 0.52% | Add +58.2% | 10,870 | $209.84 | $2M | +4,000 | +$328K |
| GPCR - Structure Therapeutics | 0.51% | Add +25.7% | 46,500 | $48.20 | $2M | +9,500 | −$332K |
| Immatics | 0.51% | Reduce −13.5% | 225,860 | $9.84 | $2M | −35,278 | −$519K |
| CLDX - Celldex Therapeutics | 0.49% | Hold | 68,518 | $31.72 | $2M | — | — |
| LXEO - Lexeo Therapeutics | 0.49% | Add +10.6% | 377,059 | $5.74 | $2M | +36,200 | −$1M |
| ALEC - Alector | 0.44% | Hold | 908,351 | $2.15 | $2M | — | — |
| VKTX - Viking Therapeutics | 0.44% | Hold | 59,516 | $32.54 | $2M | — | — |
| KURA - Kura Oncology | 0.44% | Hold | 235,868 | $8.13 | $2M | — | — |
| PROF - Profound Medical | 0.39% | Reduce −7.9% | 263,005 | $6.48 | $2M | −22,705 | −$544K |
| FULC - Fulcrum Therapeutics | 0.36% | New | 205,000 | $7.67 | $2M | +205,000 | +$2M |
| AQST - Aquestive Therapeutics | 0.35% | Reduce −2.0% | 368,415 | $4.15 | $2M | −7,500 | −$899K |
| Mediwound | 0.35% | Reduce −16.9% | 94,405 | $16.11 | $2M | −19,207 | −$576K |
| KIDS - Orthopediatrics | 0.35% | New | 95,659 | $15.87 | $2M | +95,659 | +$2M |
| RARE - Ultragenyx Pharmaceutical | 0.29% | Add +281.9% | 61,100 | $20.95 | $1M | +45,100 | +$912K |
| Engene | 0.29% | Add +14.5% | 187,353 | $6.81 | $1M | +23,708 | −$202K |
| NGNE - Neurogene | 0.26% | Add +102.5% | 56,635 | $20.16 | $1M | +28,661 | +$565K |
| SPRY - Ars Pharmaceuticals | 0.25% | Reduce −26.7% | 139,285 | $8.03 | $1M | −50,780 | −$1M |
| CTMX - Cytomx Therapeutics | 0.25% | New | 230,000 | $4.70 | $1M | +230,000 | +$1M |
| MAZE - Maze Therapeutics | 0.24% | New | 35,000 | $29.85 | $1M | +35,000 | +$1M |
| MLYS - Mineralys Therapeutics | 0.24% | Hold | 38,490 | $27.09 | $1M | — | — |
| SCYXEUR - Scynexis | 0.23% | New | 1,086,956 | $0.9169 | $997K | +1,086,956 | +$997K |
| ORIC - Oric Pharmaceuticals | 0.22% | Reduce −30.0% | 98,724 | $9.58 | $945K | −42,321 | −$208K |
| INSP - Inspire Medical Systems | 0.21% | Add +111.6% | 18,200 | $51.58 | $939K | +9,600 | +$146K |
| Polypid | 0.21% | Hold | 207,900 | $4.38 | $911K | — | — |
| TELA - Tela Bio | 0.20% | Hold | 1,441,029 | $0.6200 | $893K | — | — |
| ZBIO - Zenas Biopharma | 0.19% | New | 42,500 | $19.55 | $831K | +42,500 | +$831K |
| VRCA - Verrica Pharmaceuticals | 0.18% | Reduce −11.4% | 153,712 | $5.29 | $813K | −19,739 | −$628K |
| FATE - Fate Therapeutics | 0.15% | Hold | 550,000 | $1.20 | $660K | — | — |
| ANNX - Annexon | 0.15% | Reduce −56.8% | 117,812 | $5.54 | $653K | −155,000 | −$717K |
| ARAY - Accuray | 0.15% | Add +20.4% | 1,680,508 | $0.3881 | $652K | +285,000 | −$499K |
| NAMS - Newamsterdam Pharma | 0.15% | New | 20,000 | $32.01 | $640K | +20,000 | +$640K |
| ACET - Adicet Bio | 0.15% | Hold | 93,812 | $6.81 | $639K | — | — |
| BNTX - Biontech Se | 0.14% | Hold | 7,000 | $88.88 | $622K | — | — |
| PLRX - Pliant Therapeutics | 0.14% | New | 487,000 | $1.26 | $614K | +487,000 | +$614K |
| Compugen | 0.12% | Reduce −5.4% | 257,783 | $2.13 | $549K | −14,619 | +$132K |
| OBIO - Orchestra Biomed | 0.12% | Hold | 126,841 | $4.25 | $539K | — | — |
| FHTX - Foghorn Therapeutics | 0.12% | Reduce −11.8% | 111,859 | $4.78 | $535K | −15,000 | −$150K |
| IBIO — | 0.08% | New | 193,638 | $1.90 | $368K | +193,638 | +$368K |
| BCYC - Bicycle Therapeutics | 0.07% | Hold | 64,492 | $4.64 | $299K | — | — |
| ADCT - Adc Therapeutics SA | 0.06% | Reduce −6.5% | 72,081 | $3.75 | $270K | −5,000 | −$2K |
| KPTI - Karyopharm Therapeutics | 0.06% | Reduce −10.2% | 45,800 | $5.57 | $255K | −5,200 | −$120K |
| AUTL - Autolus Therapeutics | 0.06% | Hold | 179,316 | $1.38 | $247K | — | — |
| NMRA - Neumora Therapeutics | 0.03% | New | 70,000 | $1.95 | $137K | +70,000 | +$137K |
Showing top 50 of 82 by value
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2025 Q4
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| CATBUSD - Astria Therapeutics | 0.93% | Exit | 0 | $13.09 | $4M | −304,775 | −$4M |
| ERAS - Erasca | 0.22% | Exit | 0 | $3.72 | $947K | −254,436 | −$947K |
| BWAY - Brainsway | 0.06% | Exit | 0 | $19.05 | $247K | −12,965 | −$247K |
| CATX - Perspective Therapeutics | 0.03% | Exit | 0 | $2.76 | $138K | −50,000 | −$138K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 88 | $524M | +19.1% | 13F-HR | 8/14/2026 | 000138993326000006 |
| 2026 Q1 | 83 | $440M | +2.1% | 13F-HR | 5/15/2026 | 000138993326000004 |
| 2025 Q4 | 77 | $431M | +6.4% | 13F-HR | 2/17/2026 | 000138993326000002 |
| 2025 Q3 | 75 | $405M | +11.9% | 13F-HR | 11/14/2025 | 000138993325000008 |
| 2025 Q2 | 76 | $362M | +2.5% | 13F-HR | 8/14/2025 | 000138993225000011 |
| 2025 Q1 | 83 | $353M | −10.2% | 13F-HR | 5/15/2025 | 000138993325000002 |
| 2024 Q4 | 82 | $393M | −7.1% | 13F-HR | 2/14/2025 | 000138993225000004 |
| 2024 Q3 | 84 | $423M | +1.0% | 13F-HR | 11/14/2024 | 000138993224000020 |
| 2024 Q2 | 83 | $419M | −4.6% | 13F-HR | 8/14/2024 | 000138993224000016 |
| 2024 Q1 | 72 | $439M | +5.3% | 13F-HR | 5/15/2024 | 000138993224000012 |
| 2023 Q4 | 76 | $417M | +29.9% | 13F-HR | 2/14/2024 | 000138993224000004 |
| 2023 Q3 | 75 | $321M | −12.3% | 13F-HR | 11/14/2023 | 000138993223000010 |
| 2023 Q2 | 73 | $366M | +9.6% | 13F-HR | 8/14/2023 | 000138993323000008 |
| 2023 Q1 | 72 | $334M | −5.9% | 13F-HR | 5/15/2023 | 000138993323000006 |
| 2022 Q4 | 79 | $355M | −4.6% | 13F-HR | 2/14/2023 | 000138993323000002 |
| 2022 Q3 | 87 | $372M | +1.4% | 13F-HR | 11/14/2022 | 000138993322000010 |
| 2022 Q2 | 90 | $367M | −4.4% | 13F-HR | 8/15/2022 | 000138993322000008 |
| 2022 Q1 | 94 | $384M | −3.5% | 13F-HR | 5/16/2022 | 000138993322000006 |
| 2021 Q4 | 87 | $398M | +5.6% | 13F-HR | 2/14/2022 | 000138993322000002 |
| 2021 Q3 | 80 | $377M | — | 13F-HR | 11/15/2021 | 000138993321000011 |
About
DAFNA Capital Management LLC
20 processed 13Fs on this site · 2021 Q3–2026 Q2